Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28651089 | 0.88 | GPR119 (0.50) | GLSRECQLFAAHHPGDUSP2 | |
| SCHEMBL4224647 | 0.87 | RECQL (0.45) | GLSRECQLFAAHHPGDUSP2 | |
| SCHEMBL21987460 | 0.84 | FKBP1A (0.36) | GLSFAAHKDM4EPKMGPR119 | |
| SCHEMBL1715488 | 0.82 | GPR119 (0.52) | GLSRECQLHPGDUSP2SMN1; SMN2 | |
| SCHEMBL29301992 | 0.82 | RECQL (0.42) | GLSRECQLFAAHHPGDUSP2 | |
| SCHEMBL7516819 | 0.82 | HPGD (0.46) | GLSRECQLFAAHHPGDUSP2 | |
| SCHEMBL795969 | 0.80 | HPGD (0.53) | RECQLFAAHHPGDUSP2SMN1; SMN2 | |
| SCHEMBL796239 | 0.80 | HPGD (0.53) | RECQLFAAHHPGDUSP2SMN1; SMN2 | |
| SCHEMBL17042419 | 0.80 | GPR119 (0.39) | GLSFAAHSMN1; SMN2GPR119 | |
| SCHEMBL34468045 | 0.80 | RECQL (0.40) | GLSRECQLFAAHHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| CN-110809574-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MUTABILIS (FR) | 2019-05-28 | — | — | US | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |
| EP-3110803-B1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2017-01-19 | — | — | US | disclosed |
| EP-3110803-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Mutabilis (FR) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128333-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LABORATOIRE BIODIM (FR) | 2015-09-03 | — | — | WO | disclosed |
| EP-2913330-A1 | Condensed derivatives of imidazole useful as pharmaceuticals | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | GLS 879/4885RECQL 84/4885FAAH 3190/4885 |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MSR1, IFNAR1, NOD2 | GLS 439/4885RECQL 619/4885FAAH 3356/4885 |
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MSR1, IFNAR1, NOD2 | GLS 439/4885RECQL 619/4885FAAH 3356/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | GLS 1109/4885RECQL 164/4885FAAH 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.